H
ABBV icon

HoyleCohen’s AbbVie ABBV Stock Holding History

HoyleCohen’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$11.4M Sell
66,373
-3,409
-5% -$565K 0.86% 35
2024
Q1 		$12.7M Sell
69,782
-2,407
-3% -$415K 0.97% 30
2023
Q4 		$11.2M Buy
72,189
+1,055
+1% +$154K 0.91% 31
2023
Q3 		$10.6M Buy
71,134
+678
+1% +$99.5K 0.98% 29
2023
Q2 		$9.49M Sell
70,456
-706
-1% -$104K 0.84% 35
2023
Q1 		$11.3M Sell
71,162
-1,164
-2% -$178K 1.06% 25
2022
Q4 		$11.7M Sell
72,326
-13,618
-16% -$2.09M 1.16% 22
2022
Q3 		$11.5M Sell
85,944
-1,241
-1% -$178K 1.26% 18
2022
Q2 		$13.4M Sell
87,185
-258
-0.3% -$39.4K 1.39% 17
2022
Q1 		$14.2M Sell
87,443
-611
-0.7% -$88.8K 1.21% 21
2021
Q4 		$11.9M Sell
88,054
-248
-0.3% -$29.3K 0.99% 24
2021
Q3 		$9.53M Sell
88,302
-549
-0.6% -$62.7K 0.9% 25
2021
Q2 		$10K Sell
88,851
-199
-0.2% -$22.4K 0.78% 26
2021
Q1 		$9.64M Buy
89,050
+112
+0.1% +$12K 0.98% 25
2020
Q4 		$9.53M Buy
88,938
+48,114
+118% +$4.62M 1.1% 19
2020
Q3 		$3.58M Buy
40,824
+779
+2% +$73.3K 0.53% 54
2020
Q2 		$3.93M Buy
40,045
+1,743
+5% +$153K 0.66% 43
2020
Q1 		$2.92M Buy
38,302
+2,275
+6% +$194K 0.58% 52
2019
Q4 		$3.19M Sell
36,027
-1,599
-4% -$133K 0.51% 56
2019
Q3 		$2.85M Sell
37,626
-264
-0.7% -$18.1K 0.49% 57
2019
Q2 		$2.75M Sell
37,890
-3,186
-8% -$250K 0.48% 56
2019
Q1 		$3.31M Sell
41,076
-4,835
-11% -$396K 0.58% 52
2018
Q4 		$4.23M Sell
45,911
-614
-1% -$54K 0.87% 36
2018
Q3 		$4.4M Sell
46,525
-554
-1% -$52.5K 0.83% 39
2018
Q2 		$4.36M Sell
47,079
-849
-2% -$82.9K 0.88% 36
2018
Q1 		$4.54M Sell
47,928
-473
-1% -$52K 0.92% 36
2017
Q4 		$4.68M Buy
+48,401
New +$4.56M 0.92% 37

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

HoyleCohen's ABBV Position: Q2 2024 in Review

HoyleCohen reduced its AbbVie (ABBV) stake by 4.9% in Q2 2024, selling an estimated $565K and leaving 66,373 shares worth $11.4M. The position accounts for 0.86% of the portfolio, ranked #35.

HoyleCohen first reported a position in ABBV in Q4 2017 and has held it in 27 quarters since. The position peaked at $14.2M in Q1 2022. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

  • HoyleCohen held 66,373 shares of AbbVie worth $11.4M as of Q2 2024.
  • HoyleCohen sold 3,409 AbbVie shares in Q2 2024, an estimated $565K.
  • AbbVie made up 0.86% of HoyleCohen's portfolio in Q2 2024, its #35 holding.
  • HoyleCohen first reported a position in AbbVie in Q4 2017 and has held it in 27 quarters since.
  • HoyleCohen's AbbVie position peaked at $14.2M in Q1 2022.
  • 3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on HoyleCohen's 13F filing for Q2 2024, filed 19 Jul 2024.